Rasonque’s $39,800 monthly price tag and historic survival data set stage for blockbuster oncology launch

Key points

• FDA approved Rasonque (daraxonrasib) in 35 days for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent therapy.
• The drug's 30-day list price is $39,800, equating to an annual wholesale cost of approximately $477,000, which is more than double the price of Merck's Keytruda.
• Phase 3 trials showed a 60% reduction in death risk, with median overall survival of 13.2 months for Rasonque versus 6.7 months for standard chemotherapy.
• Analysts at Evercore ISI raised sales estimates to $2.4 billion for next year and $15.1 billion by 2034 for pancreatic cancer alone, with peak revenue potentially reaching $20.8 billion if approved for other cancers.
• Revolution Medicines launched the (ON)Path program to help patients navigate insurance, financial assistance, and side effect management, with some eligible commercially insured patients potentially paying $0 out-of-pocket.

Background

Pancreatic cancer is the third-leading cause of cancer death in the U.S., with a five-year survival rate of just 13% and approximately 67,000 new diagnoses expected in 2026. RAS mutations, particularly in the KRAS gene, are found in over 90% of cases and were long considered 'undruggable.' Rasonque represents the first FDA-approved RAS-targeting therapy broadly effective for this disease, marking a paradigm shift in treatment options for a historically difficult-to-treat cancer.

How outlets are covering it

BioPharma Dive emphasizes the commercial potential, noting the $39,800 monthly price exceeded Wall Street expectations of $25,000-$30,000 and prompted analysts to raise sales projections significantly. Yahoo Finance focuses on the financial impact on patients, detailing how out-of-pocket costs vary based on insurance coverage, with Medicare Part D discounts potentially reducing costs by 20-30% and the (ON)Path program offering assistance. Pancreatic Cancer Action Network (PanCAN) highlights the clinical breakthrough, calling it 'the most significant advance we have ever seen' and stressing the importance of biomarker testing and side effect management, with rash reported in 86% of patients and stomatitis in 54%.

Why it matters

Rasonque's approval and pricing strategy could reshape the oncology market, potentially becoming one of the fastest and highest-revenue drug launches in history. The high price point raises questions about payer coverage and access, while the drug's broad label and potential for first-line use could expand its market significantly. For patients, it offers a life-extending option for a deadly cancer with few alternatives, but the cost and side effects require careful navigation through insurance and support programs.

What to watch

Revolution Medicines is pursuing front-line approval for Rasonque through an ongoing Phase 3 trial. The company is also testing the drug in combination with chemotherapy and other targeted therapies, as well as in adjuvant settings to prevent recurrence after surgery. Analysts expect the FDA to grant additional approvals for other cancer types, potentially driving peak annual revenue to $20.8 billion. Payers may attempt to restrict first-line use due to cost, but limited alternatives for many patients may reduce friction.